Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Touyun Biotech Group's ROE % for the quarter that ended in Dec. 2025 was Negative Equity. Touyun Biotech Group's PB Ratio for the quarter that ended in Dec. 2025 was N/A.
Touyun Biotech Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was Negative Equity.
Touyun Biotech Group ROE % Adjusted to Book Value Related Terms
Touyun Biotech Group ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Touyun Biotech Group's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touyun Biotech Group ROE % Adjusted to Book Value Chart
HKSE:01332 vs SW, PKG, IP: ROE % Adjusted to Book Value Comparison
For the Packaging & Containers subindustry, Touyun Biotech Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Touyun Biotech Group ROE % Adjusted to Book Value vs Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Touyun Biotech Group's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Touyun Biotech Group's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Touyun Biotech Group (HKSE:01332) has a ROE % Adjusted to Book Value of Negative Equity% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Touyun Biotech Group and its competitors.
Is Touyun Biotech Group's ROE % Adjusted to Book Value too high?
Touyun Biotech Group's current ROE % Adjusted to Book Value is Negative Equity%. Overall, Touyun Biotech Group has a GF Score™ of 25/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Touyun Biotech Group's ROE % Adjusted to Book Value compare to SW and PKG?
Touyun Biotech Group's ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Packaging & Containers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Packaging & Containers company?
A good ROE % Adjusted to Book Value depends on the Packaging & Containers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Touyun Biotech Group and its competitors. Touyun Biotech Group's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touyun Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, Touyun Biotech Group (HKSE:01332) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.14 — trading 12.5% below its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. Touyun Biotech Group's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Touyun Biotech Group (HKSE:01332), the current ROE % Adjusted to Book Value is Negative Equity% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Touyun Biotech Group (HKSE:01332) Overvalued in 2026?
Based on GuruFocus' analysis, Touyun Biotech Group stock appears to be undervalued.
The current stock price of HK$0.14 is trading 12.5% below its estimated GF Value™ of HK$0.16.
GuruFocus considers Touyun Biotech Group to be Modestly Undervalued.
Key valuation signals for HKSE:01332:
ROE % Adjusted to Book Value: Negative Equity%
GF Value™: HK$0.16 vs. price of HK$0.14 (12.5% below fair value)
No single metric tells the full story. See the HKSE:01332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Touyun Biotech Group Ltd is principally engaged in the (i) the manufacture and sale of packaging products; (ii) investments and trading in securities and money lending, and (iii) production and sale of Chlamydomonas reinhardtii, micro-algae and related products. The company generates majority of its revenue from packaging products segment.
25GF Score
Get the complete analysis for HKSE:01332
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01332 has been successfully added to your 
